Multiple Sclerosis Updates 2016. MS is a highly variable condition that affects everyone differently, hence posing a particular challenge for the MS specialist. In this session we will review the immunology of MS regarding B and T cell activity as it applies to the disease state, and to the new disease modifying therapies available over the past 5 years. The goal of this session, is to bring awareness, and a better understanding for the APC who is providing primary care to this patient population.

Upon completion of this session, the learner will be able to:

1. Describe Immunology as it pertains to multipule sclerosis (MS).
2. Review updates regarding diagnosis and changing landscape in MS care as it pertains to the primary care provider.
3. Discuss updates for the APC regarding changing landscape of pharmacotherapy as it pertains to MS.

Conflict of Interest for Presenter:

- Leah Gaedeke has declared that she is on the speakers bureau for Genzyme, Novartis, and Genentech, and is a consultant for Genentech, Biogen and EMD-Serono. The relevant relationship with the commercial interest has been evaluated and determined to be pertinent to the content of this educational activity. The activity’s presentation will be reviewed for absence of bias that is actual/potential or real/perceived, balance in presentation, evidence-based content or other indicators of integrity, AND will be monitored at the conference to evaluate for absence of commercial bias during the presentation. Participant feedback from the activity will also be evaluated for absence of commercial bias.

- As faculty/presenter/author for this activity, the presenter(s) attest that they will provide the best available evidence for this content and present information fairly and without bias.